GWPH trial

  • Featured Story

    GWPH stock price

    The GWPH stock price soared more than 130% to $88.22 a share this morning (Monday) morning after GW Pharmaceuticals Plc. (Nasdaq ADR: GWPH) announced positive phase 3 study results for its investigational cannabidiol drug, Epidiolex.

    Epidiolex is designed to treat Dravet syndrome. Also known as severe myoclonic epilepsy of infancy (SMEI), Dravet syndrome is a type of epilepsy with often fatal seizures.

    Here's what else investors need to know...

Article Index

Why the GWPH Stock Price Soared 130% Today and What's Next

GWPH stock price

The GWPH stock price soared more than 130% to $88.22 a share this morning (Monday) morning after GW Pharmaceuticals Plc. (Nasdaq ADR: GWPH) announced positive phase 3 study results for its investigational cannabidiol drug, Epidiolex.

Epidiolex is designed to treat Dravet syndrome. Also known as severe myoclonic epilepsy of infancy (SMEI), Dravet syndrome is a type of epilepsy with often fatal seizures.

Here's what else investors need to know...